New Pham Dobesilate 500 mg (Dobesilate Calcium Hydrate)

Adult dose

Adults: Administer the following doses orally as calcium dobesilate hydrate. 1. Vascular lesions and retinopathy: 500~1000mg per day 2. Venous disease: Administer 750mg per day for 1~3 weeks, then administer 500mg per day. Take after meals with plenty of fluids. The dose may be adjusted as appropriate according to age and symptoms.

This medicine contains Dobesilate Calcium Hydrate as the main component and should not be used by certain patients. First, those who have hypersensitivity to this medicine or its components should not take this medicine. Women who are pregnant or breastfeeding should also avoid this medication. This medicine contains lactose, and it should not be administered to individuals with a genetic galactose intolerance, lactose deficiency, or glucose-galactose malabsorption. Patients with poor kidney function should be cautious. This medicine is mainly excreted through the kidneys, so dosage adjustment may be necessary for patients with renal failure. Special caution is needed for patients with severe kidney disease requiring dialysis. Patients with impaired liver function should also use this medicine carefully. If liver dysfunction occurs, it is recommended to reassess the benefits of the treatment. This medication contains sodium metabisulfite, which may cause allergic reactions in some patients. Patients with asthma are particularly sensitive to sulfites, so there is a risk of triggering an asthma attack and should be monitored. During treatment, gastrointestinal symptoms such as headache, abdominal pain, nausea, diarrhea, and vomiting, as well as joint pain and muscle pain, may occur. Liver function indicators may also rise, and skin rashes or allergic reactions, and rarely severe hypersensitivity reactions may develop, so it is essential to consult a doctor immediately if any unusual symptoms occur. Very rarely, blood-related issues may arise; if high fever or symptoms of infection appear, immediate consultation with a physician is necessary, and this medication should be discontinued. While no significant drug interactions have been reported with this medication, it is advisable to inform healthcare providers prior to testing as creatinine levels may appear falsely low in blood tests. It is safe to consult with healthcare providers and undergo necessary tests before taking this medication.

• Agranulocytosis
• neutropenia
• leukopenia
• skin rash
• allergic dermatitis
• pruritus
• urticaria
• facial edema
• anaphylactic reaction
• headache

This medicine is sensitive to light and should be stored in a dark container that protects it from light. Additionally, to maintain the effectiveness of the medication, it should be stored at room temperature between 1 degree and 30 degrees Celsius.

Appearance

White elongated tablet

Package unit

30 tablets/bottle, 90 tablets/bottle, 300 tablets/bottle